| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2481 | 2017 |
| Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data FC Bidard, DJ Peeters, T Fehm, F Nolé, R Gisbert-Criado, D Mavroudis, ... The lancet oncology 15 (4), 406-414, 2014 | 921 | 2014 |
| Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer PA Theodoropoulos, H Polioudaki, S Agelaki, G Kallergi, Z Saridaki, ... Cancer letters 288 (1), 99-106, 2010 | 365 | 2010 |
| Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer N Xenidis, M Ignatiadis, S Apostolaki, M Perraki, K Kalbakis, S Agelaki, ... Journal of Clinical Oncology 27 (13), 2177-2184, 2009 | 300 | 2009 |
| The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper M Cristofanilli, JY Pierga, J Reuben, A Rademaker, AA Davis, DJ Peeters, ... Critical reviews in oncology/hematology 134, 39-45, 2019 | 242 | 2019 |
| Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice S Agelaki, C Tsatsanis, A Gravanis, AN Margioris Infection and immunity 70 (11), 6068-6074, 2002 | 218 | 2002 |
| Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients G Kallergi, S Agelaki, A Kalykaki, C Stournaras, D Mavroudis, ... Breast cancer research 10, 1-11, 2008 | 165 | 2008 |
| Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer MA Papadaki, G Stoupis, PA Theodoropoulos, D Mavroudis, ... Molecular Cancer Therapeutics 18 (2), 437-447, 2019 | 160 | 2019 |
| Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients G Kallergi, H Markomanolaki, V Giannoukaraki, MA Papadaki, A Strati, ... Breast Cancer Research 11, 1-12, 2009 | 157 | 2009 |
| Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of … H Polioudaki, S Agelaki, R Chiotaki, E Politaki, D Mavroudis, A Matikas, ... BMC cancer 15, 1-10, 2015 | 153 | 2015 |
| Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study A Karampeazis, A Voutsina, J Souglakos, N Kentepozidis, S Giassas, ... Cancer 119 (15), 2754-2764, 2013 | 145 | 2013 |
| Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter … J Souglakos, D Mavroudis, S Kakolyris, C Kourousis, N Vardakis, ... Journal of clinical oncology 20 (11), 2651-2657, 2002 | 143 | 2002 |
| Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study C Emmanouilides, G Sfakiotaki, N Androulakis, K Kalbakis, ... BMC cancer 7, 1-7, 2007 | 136 | 2007 |
| Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial D Mavroudis, C Kourousis, N Androulakis, K Kalbakis, S Agelaki, ... American journal of clinical oncology 23 (4), 341-344, 2000 | 134 | 2000 |
| Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer A Daskalaki, S Agelaki, M Perraki, S Apostolaki, N Xenidis, ... British journal of cancer 101 (4), 589-597, 2009 | 131 | 2009 |
| Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer MA Papadaki, G Kallergi, Z Zafeiriou, L Manouras, PA Theodoropoulos, ... BMC cancer 14, 1-10, 2014 | 124 | 2014 |
| Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells G Kallergi, S Agelaki, H Markomanolaki, V Georgoulias, C Stournaras Cellular Physiology and Biochemistry 20 (6), 977-986, 2007 | 121 | 2007 |
| Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial D Mavroudis, N Malamos, A Alexopoulos, C Kourousis, S Agelaki, E Sarra, ... Annals of oncology 10 (2), 211-216, 1999 | 116 | 1999 |
| The promise of immunotherapy in head and neck squamous cell carcinoma P Economopoulou, S Agelaki, C Perisanidis, EI Giotakis, A Psyrri Annals of Oncology 27 (9), 1675-1685, 2016 | 111 | 2016 |
| Apoptotic circulating tumor cells in early and metastatic breast cancer patients G Kallergi, G Konstantinidis, H Markomanolaki, MA Papadaki, ... Molecular cancer therapeutics 12 (9), 1886-1895, 2013 | 105 | 2013 |
